Hope for powerful new cholesterol drug

The impact of a "knock your socks off" new cholesterol treatment is to be measured in a major UK study of heart disease.

The drug, anacetrapib, works by inhibiting a protein called cholesterylester transfer protein (CETP) that aids the movement of cholesterol in the blood plasma.

The REVEAL (Randomized EValuation of the Effects of Anacetrapib through Lipid-modification) trial will start in early 2011 and be coordinated at Oxford University, UK.

Around 30,000 people with some form of heart or other vascular disease will be recruited from 400 hospitals in the UK, North America, and Europe.

The drug has previously been found to cut blood levels of LDL cholesterol as effectively as statins, and boost levels of the health form of cholesterol HDL – or high density lipoprotein. So far it has been tested on about 2,000 people and found to be safe.

Researcher Dr Martin Landray of Oxford University said: "This study could mark the start of a new era of cholesterol treatment. Anacetrapib has really dramatic effects on blood levels of cholesterol, even in those already on a statin, and it appears to be well tolerated.

"The key question now is whether these cholesterol changes prevent coronary deaths and heart attacks. It is also critical to determine whether there are any unexpected side-effects over the longer term. The potential is massive, but we need a really large trial to provide a definitive answer – REVEAL is that trial."

The study will take more than six years to complete. It is being partly funded by Merck Sharp & Dohme, the manufacturers of anacetrapib.

Findings unveiled yesterday at the American Heart Association conference in Chicago, USA, suggests the drug can double levels of HDL and halve levels of the unhealthy cholesterol LDL – or low density lipoprotein.

Researchers reported findings of a study involving some 1,623 patients, who were already taking statins.

Researcher Dr Christopher Cannon, of Brigham and Women’s Hospital, Boston, Massachusetts, USA, said: "Anacetrapib has a knock-your-socks-off effect on HDL and a jaw-dropping effect on LDL.

"These changes are striking because virtually all the patients in the study were already taking cholesterol-lowering drugs and achieved previously unattainable levels of good and bad cholesterol."

, ,

Leave a Reply

Your email address will not be published. Required fields are marked *

Search

Categories

Monthly Posts

Our Clients

BSH
Practice Index